CURRICULUM VITAE

Richard R. Olson, MD

PERSONAL INFORMATION

Date of birth: April 7, 1956
Place of birth: Rockford, Illinois
Business address: Rockford Orthopedic Associates, Ltd.
5875 East Riverside Boulevard
Rockford, IL 61114
Phone 815-398-9491
Fax 815-381-7498

PRESENT PROFESSIONAL POSITIONS AND ACADEMIC RANK

Rheumatology Department Physician, Rockford Orthopedic Associates

Clinical Associate Professor of Medicine, University of Illinois College of Medicine

Active Staff Physician, OSF St. Anthony Medical Center, Rockford, IL

Courtesy Staff Physician, Rockford Health System, Rockford, IL

Courtesy Staff Physician, SwedishAmerican Hospital, Rockford, IL

EDUCATION

University:	University of Illinois, Urbana-Champaign, IL BS in Chemistry, 1978
Medical School:	University of Michigan, Ann Arbor, MI MD, 1982
Residency:	Boston City Hospital, Boston, MA Internal Medicine, 1982-1985
Fellowship:	Boston University, Boston, MA Rheumatology, 1985-1987

BOARD CERTIFICATIONS

National Board of Medical Examiners
Certificate number 267722
July 1, 1983

American Board of Internal Medicine
Specialty of Internal Medicine
Certificate number 104673
September 11, 1985

American Board of Internal Medicine
Subspecialty of Rheumatology
Certificate number 104673
November 6, 1990, renewed May 2010 (additional ten years)

MEDICAL LICENSURE

Illinois, number 036-087706

HONORS AND AWARDS

James Scholar, University of Illinois, 1976

ASHI Scholar, American Society of Histocompatibility and Immunogenetics
1991 and 1992

PREVIOUS PROFESSIONAL POSITIONS AND APPOINTMENTS

Clinical Associate and Assistant Professor of Medicine
University of Iowa, Iowa City, IA
1987-1993

EDUCATION & TEACHING

1987-1993: Clinical faculty at University of Iowa.

- Supervision of students and fellows providing outpatient and inpatient care.
- Teach clinical skills to 1st and 2nd year students.

1993-current: Clinical faculty at University of Illinois-Rockford.

- Fourth-year medical students: two-week electives in Rheumatology.
- Third-year medical students: clinical teaching sessions on arthritis.
- Second-year medical students: course director of Rheumatology lecture series, 1994-current
- Second-year medical students: lectures

PROFESSIONAL AND SOCIETY MEMBERSHIPS

Fellow, American College of Rheumatology

Member, American Society for Bone and Mineral Research

Certified Clinical Densitometrist, International Society for Clinical Densitometry

COMMITEE ACTIVITIES

Member, Quality Measures Committee, American College of Rheumatology, 2008-current

Member, Council on Rheumatology Care (CORC), American College of Rheumatology, 2009-current

President, Midwest Foundation for Orthopedic Research and Education (MFORE), Rockford Orthopedics, 2010-current

COMMUNITY ACTIVITIES

Member, Second Congregational Church

PUBLICATIONS

Wright, J, Schwartz, J.H., Olson, R., Kosowsky, J.M., and Tauber, A.I.: *Proton Secretion by the Sodium/Hydrogen Ion Antiporter in the Human Neutrophil*. J. Clin. Invest., 77:782-788, 1986

Rynes, R.I., Goldenberg, D.L., DiGiacomo, R., Olson, R., Hussain, M., and Veazey, J.: *Acquired Immune Deficiency Syndrome- Associated Arthritis*. Am. J. Med., 84:810, 1988.

Smith, H.R., and Olson, R.R.*: CD5+ B Lymphocytes in Systemic Lupus Erythematosus and Rheumatoid Arthritis*. J. Rheum., 17:833-35, 1990.

Cilursu, A.M., Goeken, J., and Olson, R.R.*: Detection of Antineutrophil Cytoplasmic Antibody in a Patient with l-Tryptophan Induced Eosiniphilia-Myalgia Syndrome*. Ann. Rheum. Dis. 50:817-19, 1991.

Olson, R.R., DeMagistris, M.T., DiTommaso, A., and Karr, R.W. *Mutations in the Third, but not the First or Second, Hypervariable Regions of DR (β1*0101) Eliminate DR1-Restricted Recognition of a Pertussis Toxin Peptide*. J. Immunol. 148:2703-2708, 1992.

Stone, M.S., Olson, R.R., Weisman, D.N., Giller, R.H., and Goeken, J.A.*: Vasculitis in the Newborn of a Mother with Cutaneous Polyarteritis Nodosa.* J. Amer. Acad. Derm. 28:101-105, 1993.

Olson, R.R., Reuter, J.J., and Scalf, K.: *Cell Surface Expression and Function of an HLA Class II Molecule With Class I Domain Configuration.* J. Exp. Med., 178:731-735, 1993.

O'Dell, J.R., Haire, C, Palmer, W., Drymalski, W., Wees, S. Blakely, K., Churchill, M., Eckhoff, P.J., Weaver, A., Doud, D., Erikson, N., Dietz, F., Olson, R., Maloley, P., Klassen, L., and Moore, G.F. *Treatment of Early Rheumatoid Arthritis with Minocycline or Placebo.* Arthritis & Rheumatism, 40:842-848, 1997.

Saag, K.G., Yazdany, J., Alexander, C., Caplan, L., Coblyn, J., Desai, S.P., Harrington, T., Liu, J., McNiff, K., Newman, E., and Olson, R. *American College of Rheumatology Quality Measurement White Paper Development Workgroup. Defining quality of care in rheumatology: The American College of Rheumatology white paper on quality measurement.* Arthritis Care and Research, 63: 2-9, 2011.

RESEARCH

G.D. Searle & Co., Co-Investigator, Clinical Protocol for a Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Oxaprozin Potassium 1200 MG QD, Oxaprozin Acid 1200 MG QD, and Placebo in the Treatment of Osteoarthritis of the Knee with 18 Week Follow-up. Protocol No. NY8-95-02-006.

Pfizer, Inc., Co-Investigator, A Randomized, Double-Blind Study Evaluating the Efficacy and Safety of the Combination of Tenidap with Methotrexate in Patients with Rheumatoid Arthritis. Protocol No. L-0273

Merck & Co., Co-Investigator, A 6-Month, Double-Blind, Placebo-Controlled, Parallel Group Study of Oral MK-0677 in Hip Fracture Patients. Protocol No. 017-01.

RESEARCH (cont.)

SmithKline Beecham Pharmaceuticals, Co-Investigator, Phase 1 Repeat Dose, Dose Rising Safety and Pharmacokinetic Trial of SKF-106615 (Atiprimod) in Patients with Rheumatoid Arthritis. Protocol No. 002.

G.D. Searle & Co., Co-Investigator, Clinical Protocol for Pilot Dose-Ranging Study to Evaluate the Safety and Efficacy of SC-58635 40 MG, 100 MG and 200 MG BID Versus Placebo in Treating the Signs and Symptoms of Osteoarthritis. Protocol No. N49-96-02013.

G.D. Searle & Co., Co-Investigator, Clinical Protocol for Pilot Dose-Ranging Study to Evaluate the Safety and Efficacy of SC-58635 40 MG, 200 MG and 400 MG BID Versus Placebo in Treating the Signs and Symptoms of Rheumatoid Arthritis. Protocol No. N49-96-02-012.

Autolmmune, Inc., Co-Investigator, A Phase II Double-Blind, Randomized, Placebo-Controlled, Four Group, Parallel, DoseRefinement Study of Oral Colloral in Adult Patients with Active Rheumatoid Arthritis. Protocol No. A1-200-007.

Wyeth-Ayerst, Co-Investigator, A Double-Blind, Crossover, Comparison of the Efficacy and Safety of 1000 MG Etodolac Extended Release (Etodolac ER) with 1000 MG Etodolac Followed by an Open-Label Section with Etodolac Extended Release for Up to One Year in Patients with Osteoarthritis of the Knee. Protocol No. 654-D-374-US.

GenDerm, Principal Investigator, An Open-Label Chronic Dosing, Multicenter Study Evaluating the Long Term Safety of Capsaicin Cream in Subjects with Osteoarthritis. Protocol No. 1066-5431-03.

RAIN, Co-Investigator, The Safety and Efficacy of Treatment of Early Rheumatoid Arthritis with Minocycline.

Boots Pharmaceuticals, Co-Investigator, A Study of the Efficacy and Safety of Flurbiprofen Local Action Transcutaneous (LAT) in the Treatment of Lateral Epicondylitis. BP1 3001.

Wyeth-Ayerst, Co-Investigator, A Double-Blind, Crossover Comparison of the Efficacy and Safety of Etodolac Extended Release with Etodolac in Patients with Osteoarthritis of the Knee.

Ortho-McNeil Pharmaceutical, Co-Investigator, An Evaluation of the Analgesic Efficacy and Safety of Ultram Compared to Ibuprofen in Subjects with Chronic Pain of Osteoarthritis.

The Purdue Frederick Company, Co-Investigator, Open-Label, Clinical Use Study of Controlled-Release Oxycodone Tablets Administered Orally Every 12 Hours for the Management of Pain. Protocol No. OC92-1101.

RESEARCH (cont.)

Merck & Co. Inc., Co-Investigator, An Open-Label Study to Evaluate the Safety and Pattern of Use of Flexeril MR in Patients with Painful Muscle Spasm.

Wyeth-Ayerst, Co-Investigator, Placebo-Controlled Comparison of the Safety and Efficacy of Two Doses of Etodolac Extended Release with Nabumetone in Patients with Osteoarthritis of the Knee. Protocol No. 654-D-371-US.

Hoechst SBU Rheumatology, Co-Investigator, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Compare the Activity and Safety of Leflunomide to Methotrexate or Placebo in Subjects with Active Rheumatoid Arthritis.

Wyeth-Ayerst, Co-Investigator, A Double-Blind Comparison of Bromfenac vs. Acetaminophen/Hydrocodone in Patients with Acute Soft Tissue Injury. Protocol No. 792-A-332-US.

Pfizer Inc., Co-Investigator, Multicenter Double-Blind Study of Two Dose Ranges of Tenidap Sodium Versus Piroxicam in Patients with Osteoarthritis of the Knee or Hip.

Pfizer Inc., Co-Investigator, Multicenter Double-Blind Study of Tenidap Sodium Alone, Naproxen Alone, and Naproxen with Auranofin.

Fidia, Co-Investigator, The Efficacy and Safety of Intra-articular Injections of Hyalgan in the Treatment of Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-and Naproxen-Controlled, Multicenter Clinical Trial.

Upjohn, Co-Investigator, A Comparison of ANSAID Tablets and Etodolac in the Treatment of Osteoarthritis of the Knee.

Wyeth-Ayerst, Co-Investigator, Placebo-Controlled Comparison of the Efficacy and Safety of Two Dosing Intervals of Orally Administered Etodolac to Naproxen in Patients with Osteoarthritis of the knee.

Pfizer Inc., Co-Investigator, Multicenter, Double-Blind, Placebo-Controlled Study of Piroxicam in Patients with Osteoarthritis of the Knee.

Pfizer Inc., Multicenter, Double-Blind, Placebo-Controlled, Fixed Dose, Dose-Response Study of CP-72, 133 in Patients with Rheumatoid Arthritis, 110-103-519.

Wyeth-Ayerst, Co-Investigator, Comparison of the Efficacy and Safety of Etodolac Extended Release with Etodolac in Patients with Active Rheumatoid Arthritis Followed by a Long-Term Safety Evaluation. Protocol No. 654-D-376-US.